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ABSTRACT 
 
 Between january 1982 and june 1993, 66 patients [48 men and 18 women, mean age 
50 years, range 21 to 77] underwent valve replacement for acute infective endocarditis. There 
were 45 aortic valve and 17 mitral valve infections. Four patients had bivalvular involvment. 
Fifty-three patients suffered from native valve endocarditis, with underlying valvular lesions 
documented for 31 patients. Staphylococci and Streptococci were responsible for 68% of the 
infections and 20% of the blood and valve cultures were negative. Refractory congestive heart 
failure was the leading surgical indication in 86% of the cases. The mean follow-up period 
was 44 months. Perioperative mortality was 6%. One and 3 years actuarial survival rates were 
respectively 88.5 % and 83 %. No early recurrence of infection was noted. Six patients (9.6%) 
needed reoperation. These data confirm that early surgical management may be considered 
with satisfactory results in complicated infective endocarditis. 
 
KEYWORDS: Endocarditis; Heart valves; Heart valve prosthesis; Heart valve disease; Heart 
failure, congestive; Surgery, cardiovascular. 
INTRODUCTION 
 
 Infective endocarditis refers to bacterial or fungal infection within the heart. It may 
occur as a complication of any infection, especially in patients with predisposing cardiac 
lesions or valvular prosthesis. Before the advent of antibiotics, it was considered as a fatal 
disease but since the introduction of penicillin in the early 1940s, cure and survival have 
become a reality (1). 
 Medical management is successful in the majority of patients, but is ineffective in 
about 25% of cases. Some patients develop acute signs and symptoms of sepsis, congestive 
heart failure or septic life-threatening septic emboli despite bactericidal antibiotics and 
intensive medical care. A second group of patients responds to antibiotic therapy but reveals 
cardiac failure secondary to valvular dysfunction. For these patients, the prognosis was worse 
before the development of cardiac surgery. Two reports from the mid-1960s described the 
first valvular replacements for endocarditis and proved that cardiac surgical procedure was 
feasible and potentially curative in the setting of sepsis and heart failure (2, 3). Implantation 
of a prosthetic device in an infected area seems paradoxical but has proved its effectiveness in 
much literature's reports (4, 5). Controversies remain concerning the appropriate time for 
surgery and early procedure is often advised. The purpose of this study is to retrospectively 
review our experience and to discuss recent literature trends on surgical management of acute 
endocarditis. 
PATIENTS AND METHODS 
 
 Between january 1982 and june 1993, 66 patients underwent valve replacement for 
acute endocarditis in our Cardiovascular Surgery Department. All of them were in the active 
phase of the infection and were operated on before the end of the planned 6 weeks of 
antibiotherapy. The medical records of these patients have been selected according to the 
following criteria: 1. clinical history compatible with endocarditis [fever, new or changing 
heart murmurs, cardiac failure, or embolic events in association with positive blood culture]; 
2. presence of characteristic operative lesions [leaflet destruction or perforation,  vegetation, 
ruptured chordae, ring abcess, or septal rupture]; 3. histopathological evidence of infective 
endocarditis [presence of microorganisms and polynuclear on tissue valves]. 
 Follow-up informations were obtained by direct or telephone contacts with the 
patients, families, or the patients physicians. No patient was lost. The follow-up period 
extended to 120 months and averaged 44 months. Follow-up was maintained for 36 months or 
more in 50% of the patients. The Berkson-Gage method was used to calculate the actuarial 
survival rates. 
RESULTS 
1. General  characteristics of the patients :There were 48 male and 18 female patients, 
with a mean age of 50 years [range 21 to 77 years]. Forty-five patients underwent aortic valve 
replacement [AVR] and 17 mitral valve replacement [MVR]. Four patients needed double 
[aortic and mitral] valve replacement [DVR]. Fifty-three operations were performed for native 
valve endocarditis [NVE] and 13 for prosthetic valve endocarditis [PVE]. Twelve PVE 
occurred more than 6 months after valve replacement but one patient developped early PVE 
in the first days following AVR for calcified aortic stenosis. 
 
 2. Indications for surgery  [Table I]: In most patients, surgery was undertaken for 
refractory heart failure related to valvular dysfunction [57 patients]. All patients were in New 
York Heart Association Functional Class IV. Emboli occured in 12 patients [18%]. Nineteen 
patients were operated on after ineffective antibiotherapy with persistent bacteremia or septic 
shock. Twenty-six patients had several conditions dictating early operation. The operative 
procedure included cardiopulmonary bypass with moderate hypothermia in all patients. Cold 
crystalloid cardioplegia with iced saline in the pericardium was used routinely for myocardial 
protection during bypass. Infected material was removed as completely as possible. 
Mechanical valves [Medtronic, Duromedics, St Jude, Carbomedics] were used for 47 
procedures. For 23 patients, age, lack of compliance to anticoagulant therapy and neurologic 
clinical conditions dictate the choice of bioprosthetic valves [Carpentier-Edwards, Mitroflow, 
St Jude]. All DVR were performed with mechanical valves. Interrupted sutures were used for 
all valve replacements. Five perforations of the interventricular septum were occluded, all 
associated with Staphylococcus infection. In 4 cases, debridment of a valve ring abscess was 
performed and then the valve was secured by stiches tied on both sides of the abscess. One 
patient needed associated coronary artery bypass grafting [CABG]. One patient underwent 
septal myomectomy for hypertrophic cardiomyopathy [HCM]. Mitral valve repair with 
vegetations resection was performed once, associated with AVR. In one case, a fistula 
between the aorta and the left auricula was closed with pericardial patch. 
 
 3. Underlying cardiac lesions  [Table II]: Endocarditis occured on a native valve in 53 
patients (80 %) [NVE] and on a previously inserted prosthesis in 13 patients (20%) [PVE] 
[bioprosthesis in 8 cases  and mechanical prosthesis in 5 cases]. In the NVE group, history of 
a previous heart lesion was documented for 31 patients (58.5%). The major origin of 
underlying lesions, in descending frequency, were rheumatic heart disease [RHD] (35%), 
congenital heart disease [CHD] (22%), myxoïd degeneration (20%) or calcified 
degenerescence (20%) of the aortic and mitral valves. One patient needed valve replacement 
for recurrent endocarditis on a native valve without any primitive underlying lesion. In the 
CHD group, 3 bicuspid aortic valves, one hypertrophic cardiomyopathy [HCM], one 
ventricular septal defect [VSD] associated with trisomy 21 and 2 mitral valve prolapses 
[MVP] were noted [Table III]. 
 
 4. Microbiology [Table IV]: The causative microorganisms included streptococcus in 
22 patients, staphylococcus in 20 patients, both streptococcus and staphylococcus in 5 
patients, and gram negative bacteria in 13 patients, mostly in association with gram positive. 
Two patients had intracellular bacteria endocarditis and only one patient developped candida 
infection. About 20% of the causative germs are unknown, with negative blood and valve 
cultures linked to previous blind antibiotic treatment, to fastidious microorganisms or to 
technical errors. 
 
 5. Contamination sources [Table V]: The most frequent contamination source was the 
oropharyngeal tract [15 patients], mostly from dental surgery procedures. The respiratory tract 
was involved in 8 cases. Miscellaneous contamination sources were found in 14 patients. 
Iatrogenic infections are more frequent in recent years, and 4 cases of endocarditis were 
secondary to cardiac catheterizations or percutaneous aortic valvuloplasty procedures. One 
PVE occured in the post-operative period after valvular replacement. In 29 cases, no 
contamination sources could be detected. Ten of these patients had negative blood culture, 
related to reasons explained above. 
 
 6. Survival  [Table VI] :Perioperative mortality [within 30 days] was 6% [n=4], and no 
early recurrence of infection was noted. Two women, aged 25 and 29, who were comatose 
before surgery died from neurological complications on postoperative day 6 and 29, 
respectively. Another woman, 77 years old, who suffered preoperatively from hemiparesis 
consecutive to a percutaneous aortic valvuloplasty procedure, died on postperative day 28 
from multiple organ failure [MOF]. The fourth patient, aged 59, suddenly presented mitral 
insufficiency on day 14 following AVR for PVE. Emergency MVR was performed. During 
operation, no infectious process was found and mitral dysfunction was related to myocardial 
infarction. The patient died 3 days later from MOF. 
 Long term survival rates were 88.5 % at 1 year and 83 % at 3 years. MVR and AVR 
survival rates were not significantly different. Short and long term survival of patients with 
mechanical prosthesis was better than with bioprosthesis. All patients from the DVR group 
are alive. Eleven patients died during follow-up [Table VII]. Two patients died from MOF in 
weeks following valve replacement with satisfactory postoperative cardiac function. One 
patient presented acute aortic bioprosthesis dysfunction from unknown origin during the 
second postoperative year. One patient died from spontaneous ascendant aortic aneurysm 
rupture more than 7 years after AVR for NVE.  
 One patient, who was not reoperated, died from late recurrent endocarditis more than 5 
years after AVR. Another patient suffered from recurrent PVE on aortic bioprosthesis 7 years 
after AVR for NVE. He was successfully treated by antibiotic administration. No patient from 
the DVR group developped recurrence of endocarditis . 
 
 7. Reoperation  [Table VIII] : Six patients underwent reoperation during the follow-
up. One patient suffered from late endocarditis recurrence on aortic bioprosthesis and needed 
reoperation on postoperative month 32. Three patients needed prosthesis remplacement for 
bioprothesis degenerescence 5, 7, and 10 years after AVR. Two patients presented valvular 
insufficiency secondary to periprosthetic leakage. One had MVR with a bioprosthesis, the 
other one AVR with a mechanical device. They needed reoperation at postoperative months 
11 and 26, respectively. All of these patients were alive 1 year after reoperation. No patient 
from the DVR group needed reoperation. 
DISCUSSION 
 Before antibiotics were introducted in the 1940s, endocarditis was inevitably fatal (1). 
Penicillin and many specific antimicrobial agents gave a real chance of cure and survival to 
the majority of treated patients but some of them developped fatal complications in spite of 
aggressive intravenous antibiotherapy. Even if sepsis is eradicated, irreversible valve lesions 
may occur and lead to refractive congestive heart failure. The first reports of successful valve 
replacements for active endocarditis in 1964 and 1965 suggested operation as a treatment 
modality for infective endocarditis (2, 3). Although valve remplacement with prosthetic 
material in an infected area seems paradoxical, it has proved its safety and effectiveness in 
many cases (6, 7). Surgical series report satisfactory short and long term survival rates, with 
acceptable recurrence and reoperation rates (8, 9). Evidence is now accumulating to indicate 
that early intervention improves prognosis and heart function in patients with fulminant 
valvular endocarditis. 
 Medical management requires bactericidal agents, used in high concentrations for a 
sufficient lengh of time in order to completely sterilize the vegetations where infecting 
organisms exist in extremely high densities and are protected from host defenses. Four to 6 
weeks of parenteral antibiotic therapy is usually recommanded. Surgical intervention before 
completion of antibiotic treatment is necessary in about 20% of the cases, for patients in 
whom congestive heart failure, persistent sepsis, recurrent emboli or a combination of these 
factor occur (10). In our review, refractive congestive heart failure dictated surgical treatment 
for 86% of our patients. Heart failure complicating endocarditis may be induced by valvular 
destruction, by conduction disturbances consecutive to conduction tissue involvement, and by 
myocardial abscesses with septal perforations. As confirmed by our series with AVR 
predominance, the morbidity and mortality from cardiac failure are greater with aortic valve 
infective endocarditis than with mitral valve involvment and can reach 50 to 90% if treated by 
medical therapy alone (11). With our patients, emboli occured in 12 cases, and persistent 
sepsis occured in 19 patients. In 26 cases, mixed causes dictated the need for early surgery 
These results are concordant with literature reports (6, 12). 
 Earlier surgical management of acute endocarditis should also be mandatory on 
several conditions. Among causative germs, fungi are particularly resistant to long term 
parenteral antibiotic treatment. Staphylococcus endocarditis are aggressive and promote early 
tissular destruction with acute valvular dysfunction, annular destruction, abcesses, or septum 
perforations (13). In our review, staphylococci were responsible for all the interventricular 
septum perforations. The features of Staphylococcus and fungal endocarditis should promote 
early procedure and valvular replacement before the advent of widespread tissular destruction 
which is always very difficult to repair. New onset of conduction disturbances [auriculo-
ventricular block, left bundle branch block], even without heart failure, suggest progression of 
the infectious process, especially septal spreading. Suppurative pericarditis is very difficult to 
sterilize (14). These two conditions indicate insufficient response to antibiotherapy and should 
require early surgery. 
 Prosthetic Valve Endocarditis is an infrequent but serious complication of valve 
replacement, associated with higher mortality and morbidity than NVE (15). PVE is more 
difficult to sterilize than NVE and rapid reintervention (valve rereplacement) is the major 
cause of improved survival in recent years (16). PVE is associated with higher incidence of 
valve ring abscesses, with progressive annular destruction resulting in valve dehiscence and 
perivalvular leak. This complication is more frequent in the aortic position and may lead to 
the need of complex reconstructions of the functional and anatomic integrity of the cardiac 
structures (13). Valve stenosis may also complicate PVE, most commonly with bioprosthetic 
valves in the mitral position. The principles of management of PVE are similar than NVE, 
and antibiotics seldom eradicate the infection. One of our patients suffered from recurrence of 
the endocarditis which was controled by antibiotherapy. Meanwhile, early surgical treatment 
may be mandatory to avoid widespread tissular destruction or acute valve dysfunction (13, 17, 
18). 
 Isolated echographic demonstration of vegetations is not a sufficient conditon for early 
surgical treatment (19). Reports are not concordant on the real significance of these 
asymptomatic vegetations on patient prognosis. For some authors, complications and 
mortality are more frequent if the size of the vegetation reach 1 cm or more, especially in the 
aortic position (20). Meanwhile, for others, the size, the morphology or the localization of 
vegetations do not predict the embolization hazard (21). Our opinion is that large obstructive 
vegetations or echographic demonstration of vegetations with evidence of systemic emboli 
clearly indicate surgical operation. In this case cerebral embolism may be fatal. 
 Fifty-three patients underwent valvular replacement for native valve endocarditis. 
According to literature (8) , the aortic is more usually involved than the mitral valve [77%, 
n=41]. Fifty-eight percent [n=31] of the patients from the NVE group presented underlying 
cardiac lesions. Since the introduction of antibiotherapy and the ageing of our european 
population, incidence of rheumatic heart disease and congenital cardiac disease have 
markedly decreased (22). Sclerosis and degenerative lesions [39%, n=12] are yet the most 
frequent underlying valvular diseases (23). Mitral valve prolapse was documented for 2 
patients from the mitral NVE group [2/8], and this frequency is also reported in literature 
(23). 
 Blood and valve cultures were negative in 20% of our patients. This can be related to 
fastidious microorganisms, like fungi or intracellular bacteria, but technical errors or previous 
blind antibiotic treatment, which is indicated before culture results in acute endocarditis, 
should be considered (24). In 68% of cases, gram-positive microorganisms were isolated. 
Streptococci are the most frequent of them, but the incidence of Staphylococcus infection is 
increasing related to iatrogenic inoculation. Some cultures were positive for several 
microorganisms, like gram negative and gram positive together or Streptococci reported from 
an early culture and Staphylococci from a later one. This can be explained by infection with 
mixed flora, but also to culture technical errors or to flora modifications secondary to lengthy 
antibiotic treatment and long stay in intensive care unit. Infections with gram negative 
microorganisms are more frequent in our series than in other literature reports where they are 
usually responsable for 1.7% to 7% of the endocarditis (8, 17, 24). We treated 2 infections 
due to obligatory intracellular microorganisms [chlamidia and ricketsia], and candida 
endocarditis occured on one aortic valve. 
 The fundamental principles of operative procedures involve meticulous debridement 
of infected tissue, extensive removal of all nonviable tissue and secure reconstruction of the 
involved area, with restoration of valve competence and repair of any additional defects, all of 
this accomplished under cover of the appropriate antibiotic therapy. Abscess cavities must be 
curetted and left in free drainage by the blood stream to avoid the complications of closed 
erosive abscesses. Large periannular abscesses, mycotic aneurysms or aortic perforations 
often require ingenious and complex reconstruction procedures, with sometimes translocation 
of the aortic valve (25), valve conduit replacement of ascending aorta (26), and pericardial or 
Dacron patch closure of defects (27). In our series, 5 septal perforations were closed and 4 
abscesses needed debridment. If valvular lesions are mild, valve repair is sometimes 
proposed, especially in mitral valve endocarditis (28). We performed only one mitral repair 
by vegetations resection, and without prosthetic ring implantation. These valve repairs, which 
require peroperative transoesophageal echographic assessment, may be interesting because 
they avoid prosthetic material insertion in the infected area (28). Partial leaflet resection, 
leaflet patching or suture, chordal shortening or transposition, and annular remodeling with or 
without prosthetic ring implantation may be performed. The only limiting factor is the extent 
of the lesions as all infected tissue must be resected. Early operation could be proposed to 
avoid extensive lesions and to allow valve repair (28, 29). 
Our perioperative death rate was 6%. One patient died from perioperative myocardial 
infarction. One 77 year old woman died from MOF and 2 young women with preoperative 
neurologic disturbances died from neurologic complications. These results concord with 
literature reports where perioperative mortality range from 5 to 20% (6, 8). Low cardiac 
output, aortic endocarditis, Staphylococcus infection, cardiac tissue destruction, PVE, and 
preoperative cerebral hemorragic infarct are the most predictive variables of perioperative 
death (7, 30), and valve replacement is very hazardous in the event of evidence of neurologic 
defects. No early recurrence of endocarditis was noted in our review, and we had only 3 late 
recurrences (5%). Reported hazard function for recurrent endocarditis signaled a high peaking 
early phase and a low constant phase for late infection recurrence (31, 32). Recurrence 
hazards for bioprosthetis and mechanical prosthesis are equal, but early recurrence hazard of 
allograft valves seems to be lower, especially in the early postoperative period. This fact is 
related to antibiotic penetration in the entire allograft device (32). Six (9%) patients in our 
series needed reoperation. One for late recurrence, 2 for paraprosthetic regurgitation and 3 for 
bioprosthesis degenerescence. Paraprosthetic regurgitation is secondary to partial prosthesis 
disinsertion due to rupture of stitches binded to oedematous and fragile tissues. This 
complication is reported to be more frequent with aortic prosthesis, especially if a valve ring 
abcess is found duringthe operation (14). 
Nowadays, surgical procedure is indicated for serious endocarditis which is not 
controled by intensive medical management. Valve replacement with perioperative 
antibiotherapy gives satisfactory results, although implantation of a prosthetic device in an 
infected area is paradoxical. The rate of early recurrence is low (8), and no early reinfection is 
reported in this series. The use of allograft valve could reduce this hazard. In this series, the 
long term recurrence rate is moderate and similar for bioprosthesis and mechanical prosthesis, 
and this fact confirms that the resistance to infection of these two types of devices is equal 
(32). The reoperation rate is higher for bioprosthesis, and this can be related to long-term 
degenerescence (Table VIII). In this review, the survival rate is higher for mechanical 
prosthesis than for bioprosthesis (Table VI), but the two populations are not comparable. High 
risk patients with preoperative neurologic defects received bioprosthesis in the hope of 
avoiding postoperative cerebral hemorrhage promoted by anticoagulation. In other cases, age, 
malignant hypertension or several contraindications to anticoagulation dictated the choice of 
bioprosthesis valves. Bioprosthetis patients are a high risk population for early and late fatal 
events and this finding is correlated by the worse postoperative survival rate. 
CONCLUSIONS 
The advent of antibiotics has dramatically improved the natural history and the 
prognosis of infective endocarditis but some patients still have life-threatening complications. 
These patients underwent surgical valve management with satisfactory results. Early 
operation is mandatory in the case of acute heart failure, systemic emboli and persistent 
sepsis. Early surgical procedure could also avoid widespread tissue destructions, especially in 
prosthetic valve endocarditis and staphylococcus infection. Valve repair, could be satisfactory 
in the case of mild mitral valve involvement. The use of allograft valvular prosthesis could 
reduce the rate of early recurrences, but this remains to be definitively proved. 
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